To identify the first molecular changes in response to disulfiram and sunitinib, mRNA expression of prostate cancer oncogenes AR, PSA, ERG and MYC was studied in disulfiram (1 μM), sunitinib (5 μM) or disulfiram-sunitinib co-exposed VCaP cells at 3-hour time point. This evidence concerns the gene KLK3 and prostate carcinoma.